Clinical Trial Detail

NCT ID NCT03374332
Title Infusional Gemtuzumab Ozogamicin Followed by Non-engraftment Donor Leukocyte Infusions for Refractory Acute Myeloid Leukemia
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors John Reagan
Indications

acute myeloid leukemia

Therapies

Gemtuzumab ozogamicin

Age Groups: adult

No variant requirements are available.